RMDResmedQ2 FY2026Earnings Analysis

StrongFundamentals score9 / 10

How is this scored?

Base score5
Revenue up more than 5% YoY+1
Net income up more than 10% YoY+2
Gross margin above 50%+1

Total9 / 10

Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.

Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →

AI Takeaway

RMD reported strong financial performance in Q2 FY2026 with significant growth in revenue and net income, driven by increased operational efficiency and robust market demand.

Revenue

$1.42B

+10.98% YoY

EPS (Diluted)

$2.68

+14.53% YoY

Gross Margin

61.8%

+3.2 pts YoY

Operating Income

$491.66M

+17.84% YoY

Filed Jan 30, 2026 · Analysis updated Jul 3, 2026 · Source: SEC EDGAR 10-Q filing

Next RMD earnings expected Oct 28, 2026

Revenue Growth, Margins & Profitability

Source: SEC XBRL

Resmed (RMD) reported Q2 FY2026 revenue of $1.42B, up 11.0% year over year. Operating margin was 34.6%, up 2.1 points from 32.5% a year earlier. RMD's fiscal Q2 FY2026 corresponds to calendar Q4 2025.

RMD vs Analyst Expectations

Last 4 quarters: 3 beats

Quarter	Actual EPS (USD)	Consensus (USD)	Result
Jun 2026	2.95	2.92	Beat +1.1%
Mar 2026	2.86	2.82	Beat +1.3%
Dec 2025This filing	2.81	2.75	Beat +2.1%
Sep 2025	2.55	2.58	Miss -1.2%

Adjusted (non-GAAP) EPS of $2.81 versus the $2.75 analyst consensus — a +2.1% beat for Dec 2025. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $2.68.

RMD Q2 FY2026 Management Discussion Highlights

Compiled by AI from this SEC filing

Revenue Growth Driven by Market Demand

RMD's revenue increased by 11.0% year-over-year to $1.42 billion, primarily due to strong demand in key markets.

Source: 10-Q Income Statement

Improved Operational Efficiency

Operating income rose by 17.8% to $491.66 million, reflecting enhanced operational efficiencies and cost management.

Source: 10-Q Income Statement

Strategic Investments Impact Cash Flow

Investing cash flow was negative at -$103.52 million due to strategic investments in growth initiatives.

Source: 10-Q Cash Flow

RMD Q2 FY2026 Risk Factors

Compiled by AI from this SEC filing · 1 high, 2 medium, 0 low

High Current Liabilities Growth

medium

Current liabilities increased by 46.5% year-over-year, which could pressure liquidity if not managed properly.

Source: 10-Q Balance Sheet

Increased Share Buybacks

medium

The company significantly increased share buybacks by 160.0%, which may impact cash reserves if continued at this pace.

Source: 10-Q Cash Flow

Dependence on Market Demand

high

RMD's revenue growth is heavily reliant on market demand, which may fluctuate due to economic conditions.

Source: 10-Q Income Statement

RMD Financial Charts & Detailed Metrics

Revenue & Net Income Trend

Margin Trend

View RMD's interactive chart on TradingViewLive price, indicators & drawing tools

Paid link→

Key Metrics

Income Statement

Metric	Current	Previous	YoY Change
Revenue $B	1.42 $B	1.28 $B	+10.98%
Cost of Revenue $M	544.08 $M	530.81 $M	+2.50%
Gross Profit $M	878.72 $M	751.28 $M	+16.96%
Operating Income $M	491.66 $M	417.24 $M	+17.84%
Net Income $M	392.59 $M	344.62 $M	+13.92%
EPS (Basic) $	2.69 $	2.35 $	+14.47%
EPS (Diluted) $	2.68 $	2.34 $	+14.53%
R&D Expense $M	90.97 $M	81.37 $M	+11.79%
SG&A Expense $M	278.40 $M	241.61 $M	+15.22%

Balance Sheet

Metric	Current	Previous	YoY Change
Total Assets $B	8.50 $B	7.14 $B	+19.07%
Current Assets $B	3.82 $B	2.84 $B	+34.65%
Total Liabilities $B	2.18 $B	1.89 $B	+15.58%
Current Liabilities $B	1.25 $B	0.85 $B	+46.50%
Stockholders' Equity $B	6.32 $B	5.25 $B	+20.33%
Cash & Equivalents $B	1.42 $B	0.52 $B	+171.50%
Long-Term Debt $M	403.92 $M	662.86 $M	-39.06%

Cash Flow

Metric	Current	Previous	YoY Change
Operating Cash Flow $MYTD	797.07 $M	634.16 $M	+25.69%
Investing Cash Flow $MYTD	-103.52 $M	-34.55 $M	-199.66%
Financing Cash Flow $MYTD	-488.62 $M	-298.30 $M	-63.81%
Dividends Paid $MYTD	175.33 $M	155.59 $M	+12.69%
Share Buybacks $MYTD	325.02 $M	124.99 $M	+160.04%
D&A $M	49.89 $M	46.44 $M	+7.42%

Key Ratios

Metric	Current	Previous	YoY Change
Gross Margin	61.8%	58.6%	+3.2 pts
Operating Margin	34.6%	32.5%	+2.0 pts
Net Margin	27.6%	—	—
ROE	6.2%	—	—
ROA	4.6%	—	—
Current Ratio	3.06	—	—
Debt to Equity	0.35	—	—

RMD Q2 FY2026 Earnings FAQ

Answers draw on this SEC filing and the data on this page

Did RMD beat earnings estimates in Q2 FY2026?

RMD reported a 14.5% increase in EPS (Diluted) to $2.68, indicating strong earnings performance, though specific estimates are not provided.

What were the key takeaways from RMD's Q2 FY2026 earnings?

Key takeaways include an 11.0% revenue increase to $1.42 billion and a 13.9% rise in net income to $392.59 million, driven by strong market demand and operational efficiency.

What risks did RMD highlight in its Q2 FY2026 report?

RMD highlighted risks such as increased current liabilities by 46.5% and dependence on market demand, which could impact future performance.

How did RMD's revenue grow in Q2 FY2026?

RMD's revenue grew by 11.0% year-over-year to $1.42 billion, driven by strong demand in key markets.

What is RMD's current financial health?

RMD shows strong financial health with a current ratio of 3.06 and a significant increase in cash and equivalents by 171.5%.

When is the next RMD earnings date?

Resmed (RMD) is next expected to report earnings on Oct 28, 2026. The date comes from the analyst earnings calendar and can shift until the company confirms it.

More RMD Earnings Reports

RMD Q3 FY2026

RMD reported strong financial performance in Q3 FY2026, with significant revenue growth and improved margins, driven by increased sales and effective cost management.

RMD FY2026

ResMed delivered roughly 10% revenue and diluted EPS growth in fiscal 2026 on strong sleep device and mask demand, but a higher effective tax rate held net income growth to single digits.

Related Earnings Analysis

Other companies in Health Care Equipment

Abbott Laboratories

Baxter International

Becton Dickinson

Boston Scientific

Dexcom

RMDResmedQ2 FY2026

StrongFundamentals score9 / 10

How is this scored?

Base score5
Revenue up more than 5% YoY+1
Net income up more than 10% YoY+2
Gross margin above 50%+1

Total9 / 10

Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.

Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →

AI Takeaway

RMD reported strong financial performance in Q2 FY2026 with significant growth in revenue and net income, driven by increased operational efficiency and robust market demand.

Quarter

Actual EPS (USD)

Consensus (USD)

Result

Jun 2026

2.95

2.92

Beat +1.1%

Mar 2026

2.86

2.82

Beat +1.3%

Dec 2025This filing

2.81

2.75

Beat +2.1%

Sep 2025

2.55

2.58

Miss -1.2%

Metric

Current

YoY Change

Revenue $B

1.42

+10.98%

Cost of Revenue $M

544.08

+2.50%

Gross Profit $M

878.72

+16.96%

Operating Income $M

491.66

+17.84%

Net Income $M

392.59

+13.92%

EPS (Basic) $

2.69

+14.47%

EPS (Diluted) $

2.68

+14.53%

R&D Expense $M

90.97

+11.79%

SG&A Expense $M

278.40

+15.22%

Metric

Current

YoY Change

Total Assets $B

8.50

+19.07%

Current Assets $B

3.82

+34.65%

Total Liabilities $B

2.18

+15.58%

Current Liabilities $B

1.25

+46.50%

Stockholders' Equity $B

6.32

+20.33%

Cash & Equivalents $B

1.42

+171.50%

Long-Term Debt $M

403.92

-39.06%

Metric

Current

YoY Change

Operating Cash Flow $MYTD

797.07

+25.69%

Investing Cash Flow $MYTD

-103.52

-199.66%

Financing Cash Flow $MYTD

-488.62

-63.81%

Dividends Paid $MYTD

175.33

+12.69%

Share Buybacks $MYTD

325.02

+160.04%

D&A $M

49.89

+7.42%

Metric

Current

YoY Change

Gross Margin

61.8%

+3.2 pts

Operating Margin

34.6%

+2.0 pts

Net Margin

27.6%

—

ROE

6.2%

—

ROA

4.6%

—

Current Ratio

3.06

—

Debt to Equity

0.35

—